This product is currently under development as an ELISA kit capable of measuring the blood biomarker NfL (Neurofilament Light chain), which reflects neurodegeneration.
NfL is a protein released into the bloodstream as a result of neuronal damage and is recognized as a representative biomarker that enables quantitative assessment of the progression of neurodegeneration.
 

Within the ATN framework, the international standard for Alzheimer’s disease diagnosis, NfL serves as the core biomarker representing:

• A (Amyloid)
• T (Tau)

and, in contrast to these,

• N (Neurodegeneration)

Through the development of this product, we aim to establish a measurement platform that covers the entire ATN (A, T, and N) spectrum.
 

In conventional measurement environments:

• Evaluation of pathology (A and T) has been possible
• Quantitative assessment of progression (N) has been limited

By incorporating NfL, it becomes possible to achieve:

• Evaluation of neurodegeneration progression
• Understanding of disease staging
• More comprehensive biomarker analysis
   

With the development of this product, we will establish a measurement platform that covers all components:
A (Amyloid)
T (Tau)
N (Neurodegeneration)

➡ Differentiation from companies offering only single‑marker solution
 

•  Current stage: Under development
•  Intended use: Research Use Only (RUO)
• Planned launch: End of 2026
   

This product represents a strategic development project that supports:

• Completion of the ATN strategy
• Expansion into high‑value biomarker domains
• Medium‑ to long‑term revenue growth
   

Our work on NfL is not merely an expansion of our product lineup. It is a reinforcement of our foundation aimed at elevating the completeness of diagnostic assessment to the next level.